Popular Articles

UBS aims $14.7 bn profit annually in next 3-5 yrs
Swiss banking major UBS today said it aims to achieve the target of about 15 billion Swiss francs (around $14.7 billion) pre-tax profits per year over the next three to five years.

letters: Painful recovery
That Tata Motors has cut the losses in Jaguar and Land Rover may be good news for Ratan Tata, who has been under fire for buying the luxury car company. Critics had said it was personal hubris rather than good business strategy that had dictated this purchase and it did seem so far that they were right.

News of the day

UCO Bank seeks shareholders' nod for fund raising
Public sector lender UCO Bank today said it will convene a meeting of its shareholders to decide whether it should come out with a follow-on public offer (FPO) or placement of shares to qualified institutional buyers to raise funds.
Public Relations

Ranbaxy to launch generic version of Flomax next year

Pharma company Ranbaxy Laboratories today said it will launch a generic version of the urinary disorder treatment drug-- Flomax, next year. - Fortis in talks to buy Lanka hospital chain - Ranbaxy exits generic drugs JV with Japanese firm - Japan"s largest drug maker Takeda plans India foray - Sunny re-rating of pharma companies - "We are moving towards a larger addressable market" - Avon to gain from nod to Ranbaxy"s drug "We will launch a generic version of the urinary disorder treatment Flomax in March 2010," Ranbaxy Laboratories CFO Omesh Sethi told reporters on the sidelines of a seminar here. "We would launch another big one in 2014," he said, without naming it. "We are doing well and expect a good revenue from domestic and global markets in the next financial year," Sethi said.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):